Gateway 2012: FOSS NIRSystems, Inc - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2012: FOSS NIRSystems, Inc



Your online Gateway to FOSS NIRSystems, Inc. in 2012

7703 Montpelier Road
Laurel, MD 20723
USA
Phone: +1-301-680-9600 / 1-800-343-2036
Fax: +1-301-236-0134

info@foss-nirsystems.com
www.foss-nirsystems.com

About FOSS NIRSystems, Inc.:

 

FOSS NIRSystems, Inc. is a unit of FOSS A/S of Denmark and the world's leading supplier of scanning near-infrared (NIR) products and services. We have over 45 years of industry experience and more than 18,000 successful installations worldwide. Headquartered in Laurel, MD, FOSS NIRSystems designs and manufactures a complete range of rapid scanning NIR spectrophotometers for laboratory and process applications. Sales, service, and support offices are located worldwide to serve our customers in the best possible way. For more information about FOSS NIRSystems and our complete product line, please contact us.


 
FOSS NIRSystems will exhibit at several shows during 2012, including:

Pittcon, Orlando, March, booth: 2509
Interphex, NYC, May, booth: 2072
SupplySide Marketplace, NYC, May, booth: 475
AAPS Annual Meeting, Chicago, October, booth: 4604
SupplySide West, Las Vegas, November, booth: 26091
EAS, NJ, November, booth: 201/203

 

New Products
and Releases
New Whitepapers

For our latest press releases, please visit: http://www.foss-nirsystems.com/news_latest.html

For FOSS pharmaceutical white papers, please visit: http://www.foss-nirsystems.com/pharmaceuticals.html

 

 

Please visit us at our booth or schedule a meeting at the show by contacting us at info@foss-nirsystems.com or by phone.

 



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here